Replies to post #173599 on Biotech Values

[DewDiligence]

You've neglected the relapse issue and the possibility of eight-week dosing.

Wrong—I’ve posted on both matters. I commented on the relapse rate in the bottommost paragraph of #msg-96648190. I commented on 8-week dosing at the time of GILD’s ‘ION’ data release in December.

(I presume from [the omission in] your latest post that you now acknowledge the qD-vs-BID issue is not as black-and-white as you thought.)